MYNZ

0.2252

5.66% -0.0135

Handel nachbörslich: .22 -0.0052 -2.31%

Mainz Biomed N V (MYNZ)

Überblick Nachrichten Preisverlauf Warum fällt MYNZ? Forum Prognose

Schlusskurs vom Vortag:

$0.2387

Offen:

$0.2387

24-Stunden-Volumen:

3.20M

Relative Volume:

1.04

Marktkapitalisierung:

$14.09M

Einnahmen:

$895.50K

Nettoeinkommen (Verlust:

$-26.30M

KGV:

-0.1179

EPS:

-1.91

Netto-Cashflow:

$-23.84M

1W Leistung:

+4.74%

1M Leistung:

-25.70%

6M Leistung:

-66.88%

1J Leistung:

-81.39%

1-Tages-Spanne:

$0.214

$0.2387

1-Wochen-Bereich:

$0.214

$0.3597

52-Wochen-Spanne:

$0.1852

$1.79

Mainz Biomed N V Stock (MYNZ) Company Profile

Firmenname

Mainz Biomed N V

Sektor

Healthcare (1196)

Branche

Diagnostics & Research (56)

Telefon

Adresse

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-11

Neueste SEC-Einreichungen

MYNZ's Discussions on Twitter

Vergleichen Sie MYNZ mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MYNZ	0.2252	14.09M	895.50K	-26.30M	-23.84M	-1.91
TMO	501.29	192.46B	42.37B	6.14B	7.78B	15.26
DHR	230.06	166.23B	23.74B	3.89B	4.98B	7.93
A	126.92	36.47B	6.50B	1.41B	1.42B	3.82
IQV	191.04	34.67B	15.32B	1.41B	1.96B	5.95
IDXX	419.83	34.38B	3.84B	866.24M	792.60M	9.80

Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2022-06-21	Eingeleitet	H.C. Wainwright	Buy

Mainz Biomed N V Aktie (MYNZ) Neueste Nachrichten

Nov 15, 2024

Mainz Biomed Considers Reverse Stock Split for Nasdaq Compliance - TipRanks

Nov 15, 2024

MAINZ BIOMED NV- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com

Nov 15, 2024

Nov 13, 2024

Thermo Fisher Scientific and Mainz Biomed Partner to Advance Colorectal Cancer Screening Technology - Citybuzz

Nov 13, 2024

Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening - Nasdaq

Nov 13, 2024

Nov 12, 2024

Mainz Biomed N.V. and Thermo Fisher Scientific Inc. Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets - Marketscreener.com

Nov 12, 2024

Mainz Biomed Partners With Thermo Fisher To Advance Colorectal Cancer Screening - Contract Pharma

Nov 12, 2024

Mainz Biomed and Thermo Fisher Scientific Sign a - GlobeNewswire

Nov 12, 2024

Mainz Biomed Partners with Thermo Fisher for Next-Gen Cancer Screening Breakthrough | MYNZ Stock News - StockTitan

Nov 12, 2024

Oct 22, 2024

Is Now The Time To Buy Mainz Biomed N.V. (NASDAQ: MYNZ) Stock? - Stocks Register

Oct 22, 2024

Mainz Biomed’s half-yearly revenue increases 4% YoY - Medical Buyer

Oct 22, 2024

Oct 21, 2024

Mainz Biomed reports revenue growth and reduced losses By Investing.com - Investing.com South Africa

Oct 21, 2024

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Oct 21, 2024

Oct 18, 2024

Mainz Biomed N : MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Form 6 K - Marketscreener.com

Oct 18, 2024

Oct 16, 2024

Financial Metrics Unveiled: Mainz Biomed N.V. (MYNZ)’s Key Ratios in the Spotlight - The Dwinnex

Oct 16, 2024

Oct 15, 2024

Mainz Biomed N.V.: Navigating Market Fluctuations with a 5.69M Market Cap - The InvestChronicle

Oct 15, 2024

Stocks of Mainz Biomed N.V. (MYNZ) are poised to climb above their peers - SETE News

Oct 15, 2024

Oct 14, 2024

Evaluating MYNZ’s financial ratios for a profitable investment - US Post News

Oct 14, 2024

Oct 11, 2024

Investors’ Faith in Mainz Biomed N.V. (MYNZ) could reap rewards if they hold on for the long haul - US Post News

Oct 11, 2024

Oct 10, 2024

Mainz Biomed Secures Additional $1.5M Funding - Yahoo Finance

Oct 10, 2024